We recently published a list of 10 Value Stocks in Ken Fisher’s Portfolio. In this article, we are going to take a look at ...

Deciphering where a publicly traded security may move to next is a deceptively difficult exercise. Especially when it comes ...

U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...

The stock's rise snapped a three-day losing streak.

The cause of death has been confirmed for Michelle Trachtenberg, the 39-year-old actress who was found dead in a New York ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Shares of Merck & Co. Inc. MRK slid 2.46% to $76.46 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.